Gavreto (Pralsetinib) Dosing Frequency
Gavreto is administered once daily, not weekly. The standard dosing regimen is 400 mg taken orally once per day until disease progression, intolerance, withdrawal of consent, or investigator decision 1, 2, 3.
Standard Dosing Regimen
- Dose: 400 mg orally once daily 1, 2, 3
- Frequency: Daily (not weekly) 1, 2, 3
- Duration: Continue until disease progression, unacceptable toxicity, withdrawal of consent, or investigator decision 3
Key Clinical Considerations
Pralsetinib is a selective RET inhibitor approved for RET-altered cancers, including RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancers 1, 3. The once-daily oral formulation provides convenient administration while maintaining therapeutic drug levels throughout the 24-hour dosing interval 1.
Efficacy with Once-Daily Dosing
- In Chinese patients with RET fusion-positive NSCLC, once-daily pralsetinib achieved objective response rates of 66.7% in pretreated patients and 83.3% in treatment-naïve patients 2
- Median progression-free survival was 11.7 months in pretreated patients and 12.7 months in treatment-naïve patients with this once-daily regimen 2
- In RET-altered thyroid cancer, once-daily dosing produced overall response rates of 71% in treatment-naïve RET-mutant medullary thyroid cancer, 60% in previously treated patients, and 89% in RET fusion-positive thyroid cancer 3
Safety Profile with Daily Administration
The most common grade 3/4 treatment-related adverse events with once-daily dosing include anemia (35.3%), decreased neutrophil count (33.8%), hypertension (17%), lymphopenia (12%), and anemia (10%) 2, 3. Only 11.8% of patients discontinued pralsetinib due to treatment-related adverse events, demonstrating good tolerability with the once-daily schedule 2.
Common Pitfall to Avoid
Do not confuse pralsetinib with weekly dosing regimens used for other cancer therapies. Unlike some immunotherapies or chemotherapy agents that may be dosed weekly or every few weeks, pralsetinib requires daily administration to maintain therapeutic drug levels and achieve optimal clinical outcomes 1, 2, 3.